Tourbillon Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Tourbillon Capital Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-200,000	Closed	-$24.8M	–	77
2018 Q2	$24.8M	Sell	200,000 -175,000	-47%	-$20.5M	0.96%	36
2018 Q1	$41.8M	Sell	375,000 -275,000	-42%	-$32.9M	1.66%	20
2017 Q4	$77.7M	Sell	650,000 -400,000	-38%	-$48.7M	2.88%	9
2017 Q3	$147M	Buy	1,050,000 +650,000	+163%	+$88.3M	3.57%	8
2017 Q2	$48.7M	Buy	+400,000	New	+$46.6M	0.94%	33
2017 Q1	–	Sell	-252,000	Closed	-$30.8M	–	81
2016 Q4	$30.8M	Buy	+252,000	New	+$30.8M	0.59%	42
2016 Q3	–	Sell	-180,000	Closed	-$21M	–	89
2016 Q2	$21M	Buy	+180,000	New	+$25.5M	0.42%	40

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Tourbillon Capital Partners's ALXN Position: Q3 2018 in Review

Tourbillon Capital Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 353,106 shares — an estimated $43.8M sold.

Tourbillon Capital Partners first reported a position in ALXN in Q2 2016 and held it in 9 quarters. The position peaked at $221M in Q3 2017. 585 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

Tourbillon Capital Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Tourbillon Capital Partners sold 353,106 Alexion Pharmaceuticals shares in Q3 2018, an estimated $43.8M.
Tourbillon Capital Partners first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 9 quarters.
Tourbillon Capital Partners's Alexion Pharmaceuticals position peaked at $221M in Q3 2017.
585 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Tourbillon Capital Partners's 13F filing for Q3 2018, filed 14 Nov 2018.